BioAsia 2026 represents a decisive shift toward execution, scale, and global competitiveness, reflecting the rapid evolution of the life sciences ecosystem
India’s pharmaceutical sector stands at a pivotal inflection point
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
The 2025 edition of the EdelGive Hurun list recognizes 24 exceptional women leaders for their philanthropic impact across critical areas
_256_384.png)
Over 700 exhibitors from APAC, Europe, the US, and beyond showcased the latest in personal care innovation
The inclusion of broad-spectrum sunscreen in the WHO EML and EMLc follows an application submitted in November 2024 by the Global Albinism Alliance
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
This is the first industry-academia collaboration in the country, initiated through the CSR route, for advancing research in the areas of immuno-therapeutics and regenerative medicines
Subscribe To Our Newsletter & Stay Updated
